相似文献
1
Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicity.
Cancer Immunol Immunother. 1992;35(1):53-8. doi: 10.1007/BF01741055.
2
Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
Cancer Res. 1992 Nov 15;52(22):6318-22.
3
Activation of the immune system of cancer patients by continuous i.v. recombinant IL-2 (rIL-2) therapy is dependent on dose and schedule of rIL-2.
Clin Exp Immunol. 1993 May;92(2):185-93. doi: 10.1111/j.1365-2249.1993.tb03378.x.
4
In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
Cancer Res. 1990 Aug 15;50(16):4906-10.
5
Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients.
J Clin Immunol. 1992 Jul;12(4):289-99. doi: 10.1007/BF00918153.
6
Peri-operative modulation of cellular immunity in patients with colorectal cancer.
Clin Exp Immunol. 1993 Oct;94(1):4-10. doi: 10.1111/j.1365-2249.1993.tb05968.x.
7
In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.
J Clin Oncol. 1987 Dec;5(12):1933-41. doi: 10.1200/JCO.1987.5.12.1933.
8
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies.
Br J Cancer. 1990 Mar;61(3):471-4. doi: 10.1038/bjc.1990.104.
9
Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial.
J Immunother (1991). 1992 May;11(4):274-85. doi: 10.1097/00002371-199205000-00006.
10
Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.
Cancer Immunol Immunother. 1992;35(4):237-45. doi: 10.1007/BF01789329.
引用本文的文献
1
Cytotoxic cell function and phenotypic analysis of peripheral blood mononuclear cells in cancer patients treated with low-dose interleukin-2 and mitomycin C.
Cancer Immunol Immunother. 1993 Sep;37(4):220-6. doi: 10.1007/BF01518514.
2
In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses.
Br J Cancer. 1994 Jun;69(6):1130-5. doi: 10.1038/bjc.1994.222.
3
Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.
Drugs. 1993 Sep;46(3):446-514. doi: 10.2165/00003495-199346030-00009.
本文引用的文献
1
Suppressor cell activity in melanoma patients. I. Relation to tumor growth an immunoglobulin levels in vivo.
Int J Cancer. 1981 Jul 15;28(1):1-9. doi: 10.1002/ijc.2910280102.
2
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.
Science. 1984 Sep 28;225(4669):1487-9. doi: 10.1126/science.6332379.
3
Lymphocytes infiltrating human breast cancers lack K-cell activity and show low levels of NK-cell activity.
Br J Cancer. 1981 Aug;44(2):166-76. doi: 10.1038/bjc.1981.167.
4
The standardization of NK cell assays for use in studies of biological response modifiers.
J Immunol Methods. 1984 Mar 30;68(1-2):235-49. doi: 10.1016/0022-1759(84)90154-6.
5
6
Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Cancer Res. 1985 Aug;45(8):3735-41.
7
The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
J Immunol. 1985 Jul;135(1):646-52.
8
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
J Exp Med. 1985 May 1;161(5):1169-88. doi: 10.1084/jem.161.5.1169.
9
10
Lymphokine activated killer (LAK) cells in patients with gastrointestinal cancer.
Gut. 1987 Nov;28(11):1420-5. doi: 10.1136/gut.28.11.1420.
Zotero 插件